

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Chas

1

1

1

Complete if Known	
Application Number	10/559,401
Filing Date	9/11/2008
First Named Inventor	C. Frank Bennett
Art Unit	1635
Examiner Name	Jane J. Zara
Attorney Docket Number	ISPH-0852USA

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **Applicant's unique citation designation number (optional):** ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. **Enter Office that issued the document by the two-letter code (WIPO Standard ST.3):** ² For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 (optional):** ² Applicant is to place a check mark here if English language Translation is attached.

The Standard of Examination is **reduced** by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application for a patent is set forth in 37 CFR 1.122 and 37 CFR 1.14. This collection of information is required to be 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Times given were obtained by individual case analysis on the amount of time it requires to complete this form and/or suggestions for reducing this burden. Should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

8

Complete if Known

<i>Application Number</i>	10/559,401
<i>Filing Date</i>	9/11/2008
<i>First Named Inventor</i>	C. Frank Bennett
<i>Art Unit</i>	1635
<i>Examiner Name</i>	Jane J. Zara
<i>Attorney Docket Number</i>	ISPH-0852USA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	ADAMS et al., "Intercellular Adhesion Molecule 1 on Liver Allografts During Rejection" Lancet (1989) 1122-1125.	
	12	AGRAWAL et al., "Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides" PNAS (1990) 87(4):1401-1405.	
	13	ANDERSON et al., "Leukocyte Adhesion Deficiency: An Inherited Defect in the Mac-1, LFA-1, and p150, 95 Glycoproteins" Ann. Rev. Med. (1987) 38:175-194.	
	14	BEVILACQUA et al., "Identification of an Inducible Endothelial-leukocyte Adhesion Molecule" PNAS (1987) 84:9238-9242.	
	15	BEVILACQUA et al., "Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutrophils Related to Complement Regulatory Proteins and Lectins" Science (1989) 243:1160-1165.	
	16	BRANCH et al., "A good antisense molecule is hard to find," TIBS (1998) 23:45-50.	
	17	BOADO et al., "Complete inactivation of target mRNA by biotinylated antisense oligodeoxynucleotide-avidin conjugates" Bioconjug. Chem. (1994) 5(5):406-410.	
	18	BORDIER et al., "Sequence-specific Inhibition of Human Immunodeficiency Virus (HIV) reverse transcription by Antisense Oligonucleotides: Comparative Study in Cell-free assays and HIV-infected cells" PNAS (1995) 92:9383-9387.	
	19	BUSEN et al., "Ribonuclease H Levels during the Response of Bovine Lymphocytes to Concanavalin A" Eur. J. Biochem. (1977) 74:203-208.	
	20	BUSEN et al., "Distinct Ribonuclease H Activities in Calf Thymus" Bur. J. Biochem. (1975) 52:179-190.	
	21	BUSEN, "The Subunit Structure of Calf Thymus Ribonuclease HI As Revealed by Immunological Analysis" J. Biol. Chem. (1982) 257:7106-7108.	
	22	CAMPBELL et al., "Intercellular Adhesion Molecule 1 is Induced on Isolated Endocrine Islet Cells by Cytokines but not Reovirus Infection" PNAS (1989) 86:4282-4286.	
	23	CAZENAVE et al., "Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides" Nucleic Acid Res. (1989) 17:4255-4273.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

8

Complete if Known

Application Number	10/559,401
Filing Date	9/11/2008
First Named Inventor	C. Frank Bennett
Art Unit	1635
Examiner Name	Jane J. Zara
Attorney Docket Number	ISPH-0852USA

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	24	CHIANG et al., "Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms" <i>J. Biol. Chem.</i> (1991) 266(27):18162-18171.
	25	CHIN "On the Preparation and Utilization of Isolated and Purified Oligonucleotides" Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on March 14, 2002.
	26	COSIMI et al., "In vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts" <i>J. Immunol.</i> (1990) 144:4604-4612.
	27	CROOKE et al., "Basic Principles of Antisense Therapeutics" <i>Antisense Research and Application</i> (1998) Chapter 1:1-50.
	28	CROOKE et al., "Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes" <i>Biochem. J.</i> (1995) 312:599-608.
	29	DASH et al., "Selective elimination of mRNAs in vivo: Complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity" <i>PNAS</i> (1987) 84:7896-7900.
	30	DEAN et al., "Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (CAM-1) mRNA by phorbol esters" <i>J. Biol. Chem.</i> (1994) 269(23):16416-16424.
	31	DUSTIN et al., "Lymphocyte Function-associated Antigen-1 (LFA-1) Interaction with Intercellular Adhesion Molecule-1 (ICAM-1) Is One of At Least Three Mechanisms for Lymphocyte Adhesion to Cultured Endothelial Cells" <i>J. Cell Biol.</i> (1988) 107:321-331.
	32	FAULL et al., "Tubular Expression of Intercellular Adhesion Molecule-1 During Renal Allograft Rejection" <i>Transplantation</i> (1989) 48:226-230.
	33	FRANK et al., "Purification and characterization of human ribonuclease HII" <i>Nucleic Acids Res.</i> (1994) 22:S247-S254.
	34	FROHMAN et al., "The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-g, tumor necrosis factor alpha, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentation" <i>J. Neuroimmunol.</i> (1989) 23:117-124.
	35	FURDON et al., "RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds" <i>Nucleic Acids Res.</i> (1989) 17(22):9191-9204.
	36	GAGNOR et al., "alpha-DNA VI: comparative study of alpha- and beta-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibition" <i>Nucleic Acid Res.</i> (1987) 15:10419-10436.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

8

Complete if Known

Application Number	10/559,401
Filing Date	9/11/2008
First Named Inventor	C. Frank Bennett
Art Unit	1635
Examiner Name	Jane J. Zara
Attorney Docket Number	ISPH-0852USA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	37	GHOSH et al., "Phosphorothioate-phosphodiester oligonucleotide copolymer, assessment for antisense application" Anticancer Drug Des. (1993) 8(1):15-32.	
	38	GILES et al., "Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides" Anticancer Drug Des. (1992) 7(1):37-48.	
	39	GILES et al., "Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures" Nucleic Acids Res. (1992) 20(4):763-770.	
	40	GODARD et al., "Antisense effects of cholesterol-oligonucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles" Eur. J. Biochem. (1995) 232(2):404-410.	
	41	GOTTIKH et al., "Alpha beta chimeric antisense oligonucleotides; synthesis and nuclease resistance in biological media" Antisense Res. Dev. (1994) 4(4):251-258.	
	42	GREVE et al., "The Major Human Rhinovirus Receptor is ICAM-1" Cell (1989) 56:839-847.	
	43	GRIFFITHS et al., "Keratinocyte Intercellular Adhesion Molecule-I (ICAM-1) Expression Precedes Dermal T Lymphocytic Infiltration in Allergic Contact Dermatitis (Rhus dermatitis)" Am. J. Pathology (1989) 135:1045-1053.	
	44	HALE et al., "Immunohistologic Analysis of the Distribution of Cell Adhesion Molecules with the Inflammatory Synovial Microenvironment" Arth. Rheum. (1989) 32:22-30.	
	45	HARLAN, "Leukocyte-Endothelial Interactions" Blood (1985) 65:513-525.	
	46	HO et al., "Treatment of Severe Lichen Planus with Cyclosporine" J. Am. Acad. Dermatol. (1990) 22:64-68.	
	47	HOKE et al., "Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection" Nucleic Acids Res. (1991) 19(20):5743-5748.	
	48	ISOBE et al., "Specific Acceptance of Cardiac Allograft After Treatment with Antibodies to ICAM-1 and LFA-1" Science (1992) 255:1125-1127.	
	49	ISOBE et al., "Early Detection of Rejection and Assessment of Cyclosporine Therapy by ¹¹¹ In Antimyosin Imaging in Mouse Heart Allografts" Circulation (1991) 84:1246-1255.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

5

of

8

Complete if Known

<i>Application Number</i>	10/559,401
<i>Filing Date</i>	9/11/2008
<i>First Named Inventor</i>	C. Frank Bennett
<i>Art Unit</i>	1635
<i>Examiner Name</i>	Jane J. Zara
<i>Attorney Docket Number</i>	ISPH-0852USA

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	50	ITAYA, "Isolation and characterization of a second Rnase H (Rnase HII) of Escherichia coli K-12 encoded by the mhb gene" PNAS (1990) 87:8587-8591.
	51	ITAYA et al., "Molecular cloning of a ribonuclease H (Rnase HII) gene from an extreme thermophile Thermus thermophilus HB8: a thermostable Rnase H can functionally replace the Escherichia coli enzyme in vivo" Nucleic Acids Research (1991) 19(16):4443-4449.
	52	ITAYA et al., "Selective cloning of genes encoding Rnase H from Salmonella typhimurium, Saccharomyces cerevisiae and Escherichia coli mhb mutant" Mol. Gen. Genet. (1991) 227:438-445.
	53	KANAYA et al., "Importance of the Positive Charge Cluster in Escherichia coli Ribonuclease HII for the Effective Binding of the S" J. Biol. Chem. (1991) 266:11621-11627.
	54	KANE, "Renaturation and Ribonuclease H: A Novel Mechanism That Influences Transcript Displacement by RNA Polymerase II In Vitro" Biochemistry (1988) 27:3187-3196.
	55	KATAYANAGI et al., "Crystal Structure of Escherichia coli Rnase HII in Complex with Mg ²⁺ at 2.8 Å Resolution: Proof for a Single Mg ²⁺ Binding Site" Proteins: Struct., Funct., Genet. (1993) 17:337-346.
	56	KATAYANAGI et al., "Three-dimensional structure of ribonuclease H from E. Coli" Nature (1990) 347:306-309.
	57	LEE et al., "Antisense gene suppression against human ICAM-1, ELAM-1 and VCAM-1 in cultured human umbilical vein endothelial cells" Shock (1995) 4(1):1-10.
	58	LIMA et al., "Binding Affinity and Specificity of Escherichia coli Rnase HII: Impact on the Kinetics of Catalysis of Antisense Oligonucleotide-RNA Hybrids" Biochemistry (1997) 36:390-398.
	59	LIMA et al., "The Influence of Antisense Oligonucleotide-induced RNA Structure on Escherichia coli Rnase HII Activity" J. Biol. Chem. (1997) 272:18191-18199.
	60	LISBY et al., "Intercellular Adhesion Molecule-1 (ICAM-1) Expression Correlated to Inflammation" Br. J. Dermatol. (1989) 120:479-484.
	61	MARLIN et al. "A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection" Nature (1990) 344:70-72.
	62	MILLER et al., "Cytokine Modulation of Intercellular Adhesion Molecule-1 Surface Expression on Human Melanoma Cells: Correlation with Adhesion of Peripheral Blood Leukocytes" Proc. Am. Assoc. Cancer Res. (1990) 31:353.

Examiner Signature		Date Considered
---------------------------	--	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

6

of

8

Complete if Known

<i>Application Number</i>	10/559,401
<i>Filing Date</i>	9/11/2008
<i>First Named Inventor</i>	C. Frank Bennett
<i>Art Unit</i>	1635
<i>Examiner Name</i>	Jane J. Zara
<i>Attorney Docket Number</i>	ISPH-0852USA

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	63	MONIA et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression" J. Biol. Chem. (1993) 268(19):14514-14522.
	64	NAKAMURA et al., "How does Rnase H recognize a DNA-RNA hybrid" PNAS (1991) 88:11535-11539.
	65	NYCE, "Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases" Expert Opinion on Investigational Drugs (1997) 6(9):1149-1156.
	66	NYCE, "DNA antisense therapy for asthma in an animal model" Nature (1997) 385:721-725.
	67	New England Biolabs 1998/99 Catalog (cover page and pages 121 and 284).
	68	NIELSEN et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide" Science (1991) 254:1497.
	69	OKAYASU et al., "A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice" Gastroenterology (1990) 98:694-702.
	70	OSBORN et al., "Direct Expression Cloning of Vasular Cell Adhesion Molecule 1, a Cytokine-Induced Endothelial Protein that Binds to Lymphocytes" Cell (1989) 59:1203-1211.
	71	PALU et al., "In pursuit of new developments for gene therapy of human diseases" Journal of Biotechnology (1999) 68:1-13.
	72	PETERSHEIM et al., "Base-Stacking and Base-Pairing Contributions to Helix Stability: Thermodynamics of Double-Helix Formation with CCGG, CCGGp, CCGGAp, ACCGGp, CCGGUp and ACCGGUp" Biochemistry (1983) 22:256-263.
	73	PIHL-CAREY, The Daily Biotechnology Newspaper, Vol 19, No 239, 1-2.
	74	REYNOLDS et al., "Rational siRNA design for RNA interference" Nature Biotechnology (2004) 22(3):326-330.
	75	RICE et al., "An Inducible Endothelial Cell Surface Glycoprotein Mediates Melanoma Adhesion" Science (1989) 246:1303-1306.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

7

of

8

Complete if Known

<i>Application Number</i>	10/559,401
<i>Filing Date</i>	9/11/2008
<i>First Named Inventor</i>	C. Frank Bennett
<i>Art Unit</i>	1635
<i>Examiner Name</i>	Jane J. Zara
<i>Attorney Docket Number</i>	ISPH-0852USA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	76	RICE et al., "Inducible Cell Adhesion Molecule 110 (ICAM-110) is an Endothelial Receptor for Lymphocytes" <i>J. Exp. Med.</i> (1990) 171:1369-1374.	
	77	ROTHENBERG et al., "Oligonucleotides as Antisense Inhibitors of Gene Expression: Therapeutic Implications" <i>J. Natl. Cancer Inst.</i> (1989) 81:1539-1544.	
	78	SAMBROOK et al., <i>Molecule Cloning, A Laboratory Manual</i> , 2nd Ed., Cold Spring Harbor Laboratory Press, 1989, Vol. 2, pg. 10.59.	
	79	SANGHIVI et al., "Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides" <i>Antisense Research and Applications</i> (1993) pages 273-288.	
	80	SHIOHARA et al., "Fixed Drug Eruption" <i>Arch. Dermatol.</i> (1989) 125:1371-1376.	
	81	STAUNTON et al., "A Cell Adhesion Molecule, ICAM-1, is the Major Surface Receptor for Rhinoviruses" <i>Cell</i> (1989) 56:849-853.	
	82	STAUNTON et al., "Primary Structure of ICAM-1 Demonstrates Interaction between Members of the Immunoglobulin and Integrin Supergene Families" <i>Cell</i> (1988) 52:925-933.	
	83	STAUNTON et al., "The Arrangement of the Immunoglobulin-like Domains of ICAM-1 and the Binding Sites for LFA-1 and Rhinovirus" <i>Cell</i> (1990) 61:243-254.	
	84	TIDD et al., "Partial protection of oncogene, antisense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups" <i>Br. J. Cancer</i> (1989) 60:343.	
	85	TIDD et al., "Evaluation of N-ras oncogene antisense, sense and nonsense sequence methylphosphonate oligonucleotide analogues" <i>Anti-Cancer Drug Des.</i> (1988) 3:117.	
	86	WALDER et al., "Role of RNase H in hybrid-arrested translation by antisense oligonucleotides" <i>PNAS</i> (1988) 85:5011-5015.	
	87	WEETMAN et al., "Expression of an Intercellular Adhesion Molecule, ICAM-1, by Human Thyroid Cells" <i>J. Endocrinol.</i> (1989) 122:185-191.	
	88	WEGNER et al., "Intercellular Adhesion Molecule-1 (ICAM-1) in the Pathogenesis of Asthma" <i>Science</i> (1990) 247:456-459.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. This burden will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>(Use as many sheets as necessary)</i>		
Sheet	8	of	8	
			Attorney Docket Number	ISPH-0852USA

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.